Neuromyelitis optica-like pathology is dependent on type I interferon response

Experimental Neurology

Volumn 247, Issue , 2013, Pages 744-747

  Khorooshi, Reza ^a   Wlodarczyk, Agnieszka ^a   Asgari, Nasrin ^a,b   Owens, Trevor ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Aquaporin 4; Astrocytes; Inflammation; Neuromyelitis optica; Type I IFN

Indexed keywords

AQUAPORIN 4; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; INTERFERON; INTERFERON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MONONUCLEAR CELL; MOUSE; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

AQP4; AQUAPORIN-4; ASTROCYTES; C′; CENTRAL NERVOUS SYSTEM; CNS; COMPLEMENT; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GFAP; GLIAL FIBRILLARY ACIDIC PROTEIN; H&E; HEMATOXYLIN AND EOSIN; IFN ALPHA/BETA RECEPTOR; IFNAR; INFLAMMATION; LFB; LUXOL FAST BLUE; MS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; NMO; TYPE I IFN;

ANIMALS; AQUAPORIN 4; CALCIUM-BINDING PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; NEUROMYELITIS OPTICA; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84881372176     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.02.005     Document Type: Article

References (21)

1. Asgari N., Owens T., Frokiaer J., Stenager E., Lillevang S.T., Kyvik K.O. Neuromyelitis optica (NMO)-an autoimmune disease of the central nervous system (CNS). Acta Neurol. Scand. 2011, 123:369-384.
2. Asgari N., Khorooshi R., Lillevang S.T., Owens T. Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. J. Neuroimmunol. 2013, 254:76-82.
3. Axtell R.C., Raman C., Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011, 32:272-277.
4. Benveniste E.N., Qin H. Type I interferons as anti-inflammatory mediators. Sci. STKE 2007, 2007:pe70.
5. Delhaye S., Paul S., Blakqori G., Minet M., Weber F., Staeheli P., Michiels T. Neurons produce type I interferon during viral encephalitis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7835-7840.
6. Ireland D.D., Stohlman S.A., Hinton D.R., Atkinson R., Bergmann C.C. Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. J. Virol. 2008, 82:300-310.
7. Kallfass C., Ackerman A., Lienenklaus S., Weiss S., Heimrich B., Staeheli P. Visualizing production of beta interferon by astrocytes and microglia in brain of la crosse virus-infected mice. J. Virol. 2012, 86:11223-11230.
8. Khorooshi R., Owens T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J. Immunol. 2010, 185:1258-1264.
9. Kim S.H., Kim W., Li X.F., Jung I.J., Kim H.J. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult. Scler. 2012, 18:1480-1483.
10. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
11. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
12. Ousman S.S., Wang J., Campbell I.L. Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J. Virol. 2005, 79:7514-7527.
13. Palace J., Leite M.I., Nairne A., Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010, 67:1016-1017.
14. Prinz M., Kalinke U. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol. Med. 2010, 16:379-386.
15. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., Merkler D., Detje C., Gutcher I., Mages J., Lang R., Martin R., Gold R., Becher B., Bruck W., Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
16. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., Mandler R.N., Weinshenker B.G., Pittock S.J., Wingerchuk D.M., Lucchinetti C.F. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
17. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
18. Saadoun S., Waters P., MacDonald C., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann. Neurol. 2012, 71:323-333.
19. Shimizu J., Hatanaka Y., Hasegawa M., Iwata A., Sugimoto I., Date H., Goto J., Shimizu T., Takatsu M., Sakurai Y., Nakase H., Uesaka Y., Hashida H., Hashimoto K., Komiya T., Tsuji S. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75:1423-1427.
20. Tanaka M., Tanaka K., Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur. Neurol. 2009, 62:167-170.
21. Teige I., Treschow A., Teige A., Mattsson R., Navikas V., Leanderson T., Holmdahl R., Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 2003, 170:4776-4784.